Evidence map›Paper›PMID 41957319›Full record

ArticleEJNMMI reports2026

[⁶⁸Ga]Ga-FAPI-46 PET/CT imaging in neuromelioidosis: a case series demonstrating potential utility in diagnosis and response assessment.

C M Mayur, Keerthana Kiran Kandula, M A Ashique Rahman, Suprava Naik, Bijayini Behera, Girish Kumar Parida, Sanjeev Kumar Bhoi, P Sai Sradha Patro, Kanhaiyalal Agrawal

Abstract read
In one paragraph

Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

C M MayurDepartment of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.
Keerthana Kiran KandulaDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.ORCID http://orcid.org/0009-0007-8361-0718
M A Ashique RahmanDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.
Suprava NaikDepartment of Radiodiagnosis, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.
Bijayini BeheraDepartmentof Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.
Girish Kumar ParidaDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.
Sanjeev Kumar BhoiDepartment of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.ORCID http://orcid.org/0000-0002-5192-7637
P Sai Sradha PatroDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India.ORCID http://orcid.org/0000-0002-8217-6565
Kanhaiyalal AgrawalDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India. nucmed_kanhaiyalal@aiimsbhubaneswar.edu.in.ORCID http://orcid.org/0000-0003-4855-8938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromelioidosis is a rare but severe manifestation of melioidosis with central nervous system (CNS) involvement, caused by gram negative saprophytic bacteria named Burkholderia pseudo-mallei and is associated with high morbidity and mortality. Early and accurate detection of active disease is crucial for appropriate management. We report a series of three cases of neuromelioidosis evaluated using Gallium-68–labelled fibroblast activation protein inhibitor ([⁶⁸Ga]Ga-FAPI) positron emission tomography/computed tomography (PET/CT). [⁶⁸Ga]Ga-FAPI, a novel molecular imaging tracer targeting activated fibroblasts, has demonstrated utility in imaging infection and inflammation in addition to malignancies. Unlike [¹⁸F]FDG (F-18 Fluorodeoxyglucose), [⁶⁸Ga]Ga-FAPI shows negligible physiological uptake in normal brain parenchyma, allowing superior lesion conspicuity. In the three cases reported, [⁶⁸Ga]Ga-FAPI PET/CT clearly demonstrated active CNS inflammatory lesions better than [¹⁸F]FDG PET-CT, facilitating accurate disease assessment and aiding clinical decision-making. The findings on [⁶⁸Ga]Ga-FAPI PET/CT correlated with the MRI findings and further it was found to be better than MRI for response evaluation in one case. This highlights the potential role of [⁶⁸Ga]Ga-FAPI PET/CT as a promising functional imaging modality in the evaluation of neuromelioidosis and other CNS infections.

Indexed as

BrainBurkholderia pseudo-malleiFDGFibroblast activation proteinPET/CT

Identifiers

PMID41957319
PMCPMC13066212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.